Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors

Abstract excerpt

Ten percent of patients with breast cancer, and probably somewhat more in patients with ovarian cancer, have inherited germline DNA mutations in the breast and ovarian cancer genes BRCA1 and BRCA2. In the remaining cases, the disease is caused by acquired somatic genetic and epigenetic alterations. Targeted therapeutic agents, such as poly ADP-ribose polymerases (PARP) inhibitors (PARPi), have emerged in treating...

Topics

Join the communities discussing this publication.

• BRCA gene mutations in cancer
• DNA Repair Mechanisms
• PARP inhibition in cancer therapy